We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
Read MoreHide Full Article
Key Takeaways
CorMedix will acquire four commercial-stage Heron products for approximately $223 million upfront.
The acquired portfolio generated $150 million in trailing 12-month revenues as of Sept. 30, 2026.
CorMedix expects $45-$60 million in annual cost synergies and immediate earnings accretion upon closing.
CorMedix Therapeutics (CRMD - Free Report) has entered into a definitive agreement to acquire substantially all the assets of Heron Therapeutics (HRTX - Free Report) , adding four commercial-stage products to its portfolio and further strengthening its presence in hospitals and other institutional care settings. The acquisition is expected to expand CorMedix’s revenue base and leverage its existing commercial infrastructure. Heron shares gained 26.5% following the announcement.
Under the terms of the agreement, CorMedix will pay $145 million in cash, subject to customary purchase price adjustments, and issue 14,583,333 shares of its common stock to Heron. Based on CorMedix’s closing share price of $5.32 on Nov. 6, the stock consideration was valued at approximately $77.6 million, bringing the upfront consideration to around $222.6 million. Heron is also eligible for additional sales-based compensation. To fund the acquisition, CorMedix secured a $150 million senior secured term loan facility from funds managed by Pharmakon Advisors, of which it expects to draw $75 million at closing.
Rationale Behind CRMD’s Acquisition of HRTX Assets
The Heron acquisition adds four commercial-stage products to CorMedix’s portfolio — Zynrelef, Aponvie, Cinvanti and Sustol. Zynrelef is an extended-release solution for postoperative pain, while Aponvie is used to prevent postoperative nausea and vomiting. Cinvanti and Sustol are indicated for the prevention of chemotherapy-induced nausea and vomiting. These products are administered in hospitals, ambulatory surgical centers and infusion centers, aligning with the institutional settings where CorMedix has established its commercial presence.
Beyond the upfront consideration, CorMedix may pay Heron up to $55 million in additional earn-out payments based on Zynrelef’s 2028 net sales. This includes a $25 million payment if sales reach at least $65 million and a further $30 million if they equal or exceed $95 million. The agreement also provides for a 5% royalty on the portion of combined annual net sales of Cinvanti, Sustol and products covered by Heron’s multi-product Development and License Agreement that exceeds $25 million in each of the calendar years 2027, 2028 and 2029.
Shares of CorMedix have plunged 52.9% so far this year against the industry’s 8.8% growth.
Image Source: Zacks Investment Research
The acquisition is expected to strengthen CorMedix’s commercial reach and diversify its revenue base. Following its acquisition of Melinta Therapeutics, the company has built a commercial platform focused on hospitals, infusion centers, dialysis clinics and other institutional care settings. Heron’s products share overlapping customers and sales channels, including hospital pharmacy and therapeutics committees, group purchasing organizations, integrated delivery networks and ambulatory surgical centers. This overlap should allow CorMedix to commercialize the acquired products through its existing infrastructure. The acquired portfolio generated approximately $150 million in trailing 12-month net product revenues as of Sept. 30, 2026, providing CorMedix with an established additional revenue stream.
The transaction also offers significant opportunities for cost savings and improved profitability. CorMedix expects to generate annualized operating cost synergies of $45-$60 million by the end of 2027, primarily through the elimination of overlapping commercial, general and administrative, and public company expenses. The company expects the acquisition to be immediately accretive to earnings and free cash flow upon closing. It projects pro forma combined revenues of $465-$490 million for 2026, while the acquired Heron assets are expected to generate $125-$150 million in pro forma revenues in 2027.
The acute-care products Zynrelef and Aponvie are the fastest-growing assets in Heron’s portfolio and offer opportunities for further commercial expansion. In particular, Zynrelef could benefit from increasing adoption of non-opioid approaches to postsurgical pain management in hospitals and surgery centers. Meanwhile, Cinvanti, Sustol and products covered by Heron’s multi-product Development and License Agreement should strengthen CorMedix’s presence in hematology and oncology supportive care, complementing its existing position with Rezzayo, which is used to treat candidemia and invasive candidiasis and is also being developed for prophylaxis of invasive fungal disease in certain transplant patients.
The financing arrangement with Pharmakon provides an initial $75 million draw to support the acquisition, with an additional $75 million tranche available at CorMedix’s discretion through June 30, 2028, for potential business development opportunities. The transaction is not subject to a financing contingency. It remains subject to approval by Heron stockholders, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and other customary closing conditions. The acquisition is expected to close in the first quarter of 2027. Upon completion of the transaction, Heron is expected to remain publicly traded, retaining its CorMedix shares, rights to potential earn-out payments and royalties, and certain other assets.
Over the past 30 days, earnings per share estimates for TG Therapeutics remained unchanged at 83 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from $2.65 to $2.66. TGTX’s shares have surged 112.6% year to date.
TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with an average surprise of 184.65%.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.04 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.19. AMRX’s shares have climbed 68.9% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.
View the Zacks #1 Rank List
Image: Bigstock
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
Key Takeaways
CorMedix Therapeutics (CRMD - Free Report) has entered into a definitive agreement to acquire substantially all the assets of Heron Therapeutics (HRTX - Free Report) , adding four commercial-stage products to its portfolio and further strengthening its presence in hospitals and other institutional care settings. The acquisition is expected to expand CorMedix’s revenue base and leverage its existing commercial infrastructure. Heron shares gained 26.5% following the announcement.
Under the terms of the agreement, CorMedix will pay $145 million in cash, subject to customary purchase price adjustments, and issue 14,583,333 shares of its common stock to Heron. Based on CorMedix’s closing share price of $5.32 on Nov. 6, the stock consideration was valued at approximately $77.6 million, bringing the upfront consideration to around $222.6 million. Heron is also eligible for additional sales-based compensation. To fund the acquisition, CorMedix secured a $150 million senior secured term loan facility from funds managed by Pharmakon Advisors, of which it expects to draw $75 million at closing.
Rationale Behind CRMD’s Acquisition of HRTX Assets
The Heron acquisition adds four commercial-stage products to CorMedix’s portfolio — Zynrelef, Aponvie, Cinvanti and Sustol. Zynrelef is an extended-release solution for postoperative pain, while Aponvie is used to prevent postoperative nausea and vomiting. Cinvanti and Sustol are indicated for the prevention of chemotherapy-induced nausea and vomiting. These products are administered in hospitals, ambulatory surgical centers and infusion centers, aligning with the institutional settings where CorMedix has established its commercial presence.
Beyond the upfront consideration, CorMedix may pay Heron up to $55 million in additional earn-out payments based on Zynrelef’s 2028 net sales. This includes a $25 million payment if sales reach at least $65 million and a further $30 million if they equal or exceed $95 million. The agreement also provides for a 5% royalty on the portion of combined annual net sales of Cinvanti, Sustol and products covered by Heron’s multi-product Development and License Agreement that exceeds $25 million in each of the calendar years 2027, 2028 and 2029.
Shares of CorMedix have plunged 52.9% so far this year against the industry’s 8.8% growth.
Image Source: Zacks Investment Research
The acquisition is expected to strengthen CorMedix’s commercial reach and diversify its revenue base. Following its acquisition of Melinta Therapeutics, the company has built a commercial platform focused on hospitals, infusion centers, dialysis clinics and other institutional care settings. Heron’s products share overlapping customers and sales channels, including hospital pharmacy and therapeutics committees, group purchasing organizations, integrated delivery networks and ambulatory surgical centers. This overlap should allow CorMedix to commercialize the acquired products through its existing infrastructure. The acquired portfolio generated approximately $150 million in trailing 12-month net product revenues as of Sept. 30, 2026, providing CorMedix with an established additional revenue stream.
The transaction also offers significant opportunities for cost savings and improved profitability. CorMedix expects to generate annualized operating cost synergies of $45-$60 million by the end of 2027, primarily through the elimination of overlapping commercial, general and administrative, and public company expenses. The company expects the acquisition to be immediately accretive to earnings and free cash flow upon closing. It projects pro forma combined revenues of $465-$490 million for 2026, while the acquired Heron assets are expected to generate $125-$150 million in pro forma revenues in 2027.
The acute-care products Zynrelef and Aponvie are the fastest-growing assets in Heron’s portfolio and offer opportunities for further commercial expansion. In particular, Zynrelef could benefit from increasing adoption of non-opioid approaches to postsurgical pain management in hospitals and surgery centers. Meanwhile, Cinvanti, Sustol and products covered by Heron’s multi-product Development and License Agreement should strengthen CorMedix’s presence in hematology and oncology supportive care, complementing its existing position with Rezzayo, which is used to treat candidemia and invasive candidiasis and is also being developed for prophylaxis of invasive fungal disease in certain transplant patients.
The financing arrangement with Pharmakon provides an initial $75 million draw to support the acquisition, with an additional $75 million tranche available at CorMedix’s discretion through June 30, 2028, for potential business development opportunities. The transaction is not subject to a financing contingency. It remains subject to approval by Heron stockholders, the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act and other customary closing conditions. The acquisition is expected to close in the first quarter of 2027. Upon completion of the transaction, Heron is expected to remain publicly traded, retaining its CorMedix shares, rights to potential earn-out payments and royalties, and certain other assets.
CorMedix Inc Price and Consensus
CorMedix Inc price-consensus-chart | CorMedix Inc Quote
CRMD’s Zacks Rank & Stocks to Consider
CorMedix currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are TG Therapeutics (TGTX - Free Report) and Amneal Pharmaceuticals (AMRX - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for TG Therapeutics remained unchanged at 83 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from $2.65 to $2.66. TGTX’s shares have surged 112.6% year to date.
TG Therapeutics’ earnings missed estimates in three of the trailing four quarters and beat in the remaining one, with an average surprise of 184.65%.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.04 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.19. AMRX’s shares have climbed 68.9% year to date.
Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.